No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk Patients Identified Through ctDNA-based MRD Assessment After CRC Resection By Ogkologos - June 22, 2026 228 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR Two novel bispecific antibodies in combination with chemotherapy show efficacy in neuroendocrine carcinomas Sacituzumab tirumotecan plus pembrolizumab significantly prolongs progression-free survival in advanced non-small cell lung cancer Adding Abiraterone to ADT and Docetaxel Improves Survival in Metastatic Prostate Cancer MOST POPULAR Glucose Control Key in Reducing Cancer Risk for People with Type... December 7, 2021 Quizartinib Approval Adds New Treatment Option for AML, Including in Older... August 15, 2023 Patient Guide on Bone Health in Cancer Now Available Also in French January 19, 2026 细针穿刺活检：如何准备和会发生什么 March 8, 2023 Load more HOT NEWS Can Using a Microwave Cause Cancer? Three-Drug Regimen Improves Protection against GVHD after Stem Cell Transplant A ‘sponge on a string’ test to detect oesophageal cancer earlier Navigating Your Care During Long-Term Cancer Survivorship
